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Background: Resting heart rate (RHR) is an established risk factor for cardiovascular disease (CVD), 
but long-term individual RHR trajectories and their effect on CVD morbidity and mortality have not 
yet been described. 
Methods: This large population-based longitudinal study included 14,208 men and women aged 20 
years or older, not pregnant, and not using blood pressure medications, who attended at least two of 
the three Tromsø Study surveys conducted between 1986 and 2001. RHR was measured using an 
automated Dinamap device. Participants were followed up from 2001 to 2012 with respect to 
myocardial infarction (MI), atrial fibrillation, ischemic stroke, CVD death, and total death. The Proc 
Traj statistical procedure was used to identify RHR trajectories. 
Results: Five common long-term RHR trajectories were identified: low, moderate, decreasing, 
increasing, and elevated. In men, an elevated RHR trajectory was independently associated with an 
increased risk of MI when low RHR trajectory was used as a reference (hazard ratio 1.83, 1.11-3.02). 
Risk of total death in men was lowest in the low RHR trajectory group and highest in the increasing 
and elevated RHR trajectory groups. In women, the association between RHR trajectories and MI was 
similar to that in men, but it was not significant. 
Conclusions: Among the five long-term RHR trajectories we identified, increasing and elevated 
trajectories were associated with an increased risk of MI and total death in men. Our results suggest 
that changes in long-term individual RHR in the general population may provide additional prognostic 
information. 
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Resting heart rate (RHR) is an easily measured, modifiable cardiovascular parameter. To date, there is 
a lot of evidence that single measures of RHR predict cardiovascular disease (CVD) morbidity and 
mortality independently of traditional risk factors in both men and women (1-9). RHR has declined 
remarkably over the last decades in the general population in Europe, and CVD incidence has 
declined in turn (10-14). However, individual changes in RHR over time and their effect on CVD 
morbidity and mortality in the general population are poorly described. The Paris Prospective Study 1 
showed that change in 5-year RHR was an independent predictor of total mortality in healthy middle-
aged men, with a decrease in RHR being favorable and an increase unfavorable (15). A large 
population-based cohort study from Norway showed a U-shaped association between changes in 10-
year RHR and ischemic heart disease (IHD) mortality and total mortality in both men and women, 
suggesting that an individual decrease in RHR was not beneficial with respect to mortality (16). The 
Cardiovascular Health Study concluded that variation in RHR over four years was a predictor of 
mortality in older adults whereas trend in RHR was not (17). Neither variation nor trend in RHR over 
four years was associated with incident myocardial infarction (MI). Another paper based on the 
Cardiovascular Health Study data concluded that elevations in RHR over 6 years were associated with 
an increased risk of mortality (18). 
The patterns of change in RHR over time vary between individuals. These individual patterns 
of change in long-term RHR, as well as their effect on CVD, remain unknown. This study aimed to 
identify groups of men and women with common RHR trajectories in the Tromsø Study from 1986 to 
2001, and to determine the associations between these trajectories and the risk of incident MI, incident 





Study design and participants 
The Tromsø Study is a single-center population-based longitudinal study and has been described in 
detail elsewhere (19). Briefly, total birth cohorts as well as random samples from the general 
population of Tromsø, Northern Norway were invited to participate in six surveys. Invitations and the 
Tromsø Study questionnaire were sent to all prospective participants by mail. Participants completed 
the questionnaire at home and brought it to the survey. During the survey, trained personnel reviewed 
the questionnaire, performed a physical examination, and collected blood according to standardized 
protocols. In the present report we considered the 1986-87, 1994-95, and 2001 surveys, as RHR was 
measured in the same way and to allow for a longer follow-up period. The lowest participation rate of 
the three surveys considered was 75%. 
We excluded information from surveys at which an individual was pregnant and/or had 
missing values for any of the considered variables at that survey. We also excluded information from 
all surveys of individuals who reported they had ever used blood pressure medication. Finally, we 
excluded information from all surveys of individuals who died or emigrated before 28 August 2001, 
and those who attended only one of the three surveys. Following all exclusions, 14,208 men and 




Resting heart rate and other risk factors for cardiovascular disease 
Information on current pregnancy (yes, no), use of blood pressure medication (yes, no), leisure time 
physical activity (sedentary, moderate, active/highly active), and daily cigarette smoking (yes, no) 
was taken from the Tromsø Study questionnaire. Questions on leisure time physical activity were 
different in the 1994-95 survey and for those 70 years of age or older in the 2001 survey; therefore we 
regrouped these answers to correspond to the categories used in the other surveys (20). 
At each of the three surveys, RHR and blood pressure were measured using the Dinamap 
Vital Signs Monitor 1846 (Critikon Inc., Tampa, FL, USA) – an automated, non-invasive, 
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microprocessor-controlled device (21). The proper cuff size was selected out of four available 
according to the circumference of the upper right arm (10). After being seated for 2 minutes with the 
cuff on, three RHR and blood pressure measurements were taken at 1-minute intervals. We used the 
mean of the last two RHR (in beats per minute, bpm) and systolic blood pressure (SBP, in mmHg) 
measurements in the analyses. Body weight and height were measured with light clothing and without 
shoes, and were used to calculate body mass index (BMI, kg/m2). 
Non-fasting serum levels of total cholesterol, high-density lipoprotein (HDL) cholesterol, and 
triglycerides (mmol/L) were determined by the Department of Clinical Chemistry, Department of 
Medical Biology, University Hospital of North Norway, Tromsø (10). 
 
Follow-up and identification of outcomes 
Follow-up began at the date of attendance of the 2001 survey for all those who attended. For those 
who did not attend the 2001 survey, follow-up started on 28 August 2001 (the median date of the 
2001 survey). All participants were followed through 31 December 2012 for incident non-fatal or fatal 
MI, incident non-fatal or fatal AF, incident non-fatal or fatal IS, CVD death, and total death. All CVD 
events were identified by linkage to the diagnosis registry at the University Hospital of North Norway 
(outpatient diagnoses included) and the National Causes of Death Registry, through a broad search for 
the International Classification of Diseases (ICD) Revision 9 codes 410-414, 427, 428, 430-438, and 
798-799; and ICD Revision 10 codes I20-I25, I46-I48, I50, I60-I69, R96, R98, and R99. The 
University Hospital of North Norway is the only hospital serving the community under study; the next 
nearest hospital is located approximately 250 km away by road (148 km by air). The National Causes 
of Death Registry covers individuals registered as living in Norway at the time of their death, without 
regard to whether they died in Norway or abroad. 
An independent endpoint committee validated all the CVD events found in the linkage. The 
committee first sought validation in hospital medical records, after which they turned to manual 
searches of paper records (used until 2001), and electronic text searches of digital records to find 
notes on all outcomes in participants with one or more of the diagnoses mentioned above. Finally, in 
addition to the fatal events information from the National Causes of Death Registry and death 
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certificates, the committee collected relevant information from autopsy reports and records from 
nursing homes, ambulance services, and general practitioners. The definition and ascertainment of 
incident MI, AF, and IS used in the validation process has been described in detail elsewhere (22). 




All analyses were sex-specific and performed using SAS 9.4 (SAS Institute, Cary, NC, USA). Long-
term RHR trajectory groups were determined using latent class models (SAS Proc Traj) (23, 24) and 
the year of the survey was used as the time scale. Bayesian Information Criterion was used to assess 
the model fit. After testing models with different numbers of trajectory groups, we chose to use five 
groups. Indeed, this fit better than four groups, and increasing the number of trajectory groups led to 
small group sizes. Thus in our final model we had five trajectories up to quadratic order terms. The 
posterior predicted probability of belonging to each of the five RHR trajectory groups was then 
calculated for each individual, and individuals were assigned to a trajectory group based on the 
highest posterior probability. 
 Descriptive characteristics of the RHR trajectory groups are presented as means (standard 
deviations) and numbers (percentages). Means and percentages were adjusted for age between the 
surveys and the RHR trajectory groups using linear mixed models or generalized estimating 
equations, respectively. 
 Cox proportional hazard regression analysis was used to estimate associations between 
belonging to a certain RHR trajectory group and the risk of each investigated outcome. In the analysis 
of morbidity end-points, we excluded those who had had the event of interest or had moved from 
Tromsø before the start of follow-up; those who moved or died of other causes after the start of 
follow-up were censored. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were 
calculated for each trajectory group, using the low RHR trajectory group as a reference. HRs were 
adjusted first for age alone, and then for age and other CVD risk factors: SBP, total cholesterol, HDL 
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cholesterol, triglycerides, BMI, leisure time physical activity, and smoking status. Smoking status was 
measured at the last survey attended. For the other covariates we used mean across the surveys values. 
 
Ethical considerations 
The Tromsø Study was approved by the Data Inspectorate and by the Regional Committee for 
Medical Research Ethics, North Norway, and was performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki and its later amendments. All participants provided 





We found five common long-term RHR trajectory groups in our study sample and named them 
according to their visual shape: low, moderate, decreasing, increasing, and elevated (Figure 2). Out of 
6898 men in the study sample, 22.4% were in the low RHR trajectory group, 53.9% were in the 
moderate trajectory group, 11.0% in the decreasing trajectory group, 10.1% in the figure 
increasing trajectory group, and 2.7% in the elevated trajectory group. Corresponding numbers in 
women (n=7310) were 24.6%, 58.6%, 8.6%, 6.9%, and 1.3%, respectively. A supplementary figure 
demonstrates both means and individual values of RHR by the surveys and by the trajectory groups. 
In general, women had slightly higher RHRs than men. Over the years, mean RHR decreased to a 
different extent in all the RHR trajectory groups except the increasing group in both sexes and the 
elevated group in women. 
 Mean age was similar across the RHR trajectory groups in both men (Table 1) and women 
(Table 2). Age-adjusted mean SBP in 1986-87 was higher in the elevated RHR trajectory group in 
both sexes, and over the years it increased in all the groups except the decreasing RHR trajectory 
group in women. The largest increase in SBP was in the increasing and the elevated RHR trajectory 
groups. The levels of total and HDL cholesterol were more favorable in the low RHR trajectory group 
in both sexes, and these levels decreased during the survey period in all the groups. Triglyceride 
levels in 1986-87 were higher in the decreasing and elevated RHR trajectory groups, and the highest 
increase in triglycerides over the survey period was seen in the increasing RHR trajectory group. BMI 
increased over the survey period in all the RHR trajectory groups. 
Men (Table 1) and women (Table 2) in the low RHR trajectory group were more physically 
active, and the level of leisure time physical activity decreased gradually from the low RHR to the 
elevated RHR trajectory group. Over the years, the level of leisure time physical activity increased in 
most of the trajectory groups, especially in women, although there was no clear association between 
RHR trajectory groups and changes in physical activity. In 1986-87 the highest proportion of smokers 
was observed in the decreasing RHR trajectory group and the lowest proportion in the low RHR 
trajectory group in both sexes. The proportion of smokers decreased over time in all the groups except 
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the low and the increasing RHR trajectory groups in women. It decreased the most in the decreasing 
RHR trajectory group. 
In men, being in the moderate, decreasing, increasing, or elevated RHR trajectory groups 
compared to the low RHR group was a marker of a gradually increasing risk of MI (Table 3). 
Elevated RHR trajectory independently increased the risk of MI by 83% when compared to low RHR 
trajectory. The RHR trajectories had no effect on the risk of AF and IS in men. The independent risk 
of CVD death in men was 86% higher in the increasing RHR trajectory group compared to the low 
trajectory group. Adjusted HRs of total death were 1.26 (95% CI: 1.02-1.56) for the moderate, 1.37 
(95% CI: 1.03-1.82) for the decreasing, 1.82 (95% CI: 1.40-2.38) for the increasing, and 2.44 (95% 
CI: 1.69-3.53) for the elevated trajectory groups.  
In women, the age-adjusted risk of MI was 1.68 (95% CI: 1.11-2.55), 2.52 (95% CI: 1.46-
4.36), and 3.33 (95% CI: 1.29-8.62) times higher in the moderate, increasing, and elevated RHR 
trajectory groups, respectively, compared to the low trajectory group, but these associations became 
insignificant after additional adjustment for other CVD risk factors (Table 3). Among women, 
decreasing RHR seemed to be protective for AF compared to low RHR: adjusted HR=0.31 (95% CI: 
0.14-0.68). We did not observe any significant association between the RHR trajectory groups and IS, 





Using trajectory analysis, we identified five common long-term RHR trajectories, which reflected 
individual RHR change over the 15-year survey period. These long-term individual RHR trajectories 
provided additional information to assess the risk of CVD events. We found that a steadily elevated 
RHR over the survey period independently increased the risk of MI in men compared to a steadily low 
RHR. A similar, but insignificant association was also seen in women. Low RHR trajectory was 
associated with a lower risk of death in men compared to other trajectories, and this was most 
pronounced when low RHR trajectory was compared to increasing and elevated RHR trajectories. The 
decreasing RHR trajectory was associated with a lower risk of AF in women. 
We found three population-based studies that estimated the health effect of individual change 
in RHR over time. The Paris Prospective Study 1 from 2009 included 5139 healthy men aged 42 to 53 
years (15). RHR change was calculated as the difference between RHR at inclusion and after 5 years, 
and then divided into decreased, unchanged, and increased groups. Participants were followed up for 
death for more than 20 years. The authors concluded that men with a decreased RHR had a 14% 
decreased mortality risk, whereas men with an increased RHR had a 19% increased mortality risk 
compared to the unchanged group. The Nord-Trøndelag County Health Study (HUNT) from Norway 
included both men and women aged 20 years or older without CVD (n=29,325) (16). RHR was 
measured twice at an interval of approximately 10 years, and the difference was calculated. 
Participants were followed up with respect to mortality during a mean of 12 years. The conclusion 
was that an increase in RHR over a 10-year period was associated with an increased risk of IHD and 
all-cause death, but a decrease in RHR showed no benefit. 
These two studies used the difference in RHR at two time points to determine temporal 
changes (15, 16). However, this measure cannot provide a comprehensive picture of RHR changes 
over a long time period. The Paris paper clearly demonstrated the interaction effect between baseline 
RHR and RHR change over time: in men with a low baseline RHR the effect of RHR change during 5 
years was not as strong as in men with high baseline RHR (15). In the Norwegian study the 
associations were adjusted for baseline RHR, but the authors did not check whether baseline RHR 
was an effect modifier (16). However, they showed that in a subgroup with a baseline RHR between 
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70 and 85 bpm, a decrease in RHR over a 10-year period was associated with a 40% lower risk of 
dying from IHD compared to those whose RHR remained stable. Our trajectory analysis approach 
allowed us to use three RHR measurements and to identify more realistic and prudent long-time 
patterns in RHR, taking into account both baseline level and temporal change in RHR. Furthermore, 
the Paris study measured RHR by the wrist palpation method (15). In the Norwegian study, RHR at 
baseline was measured by wrist palpation during 15 seconds, but after 10 years they switched to a 
Dinamap automated device (16). Indeed, palpation values may be subject to measurement error. 
The Cardiovascular Health Study from USA included 1991 men and women aged 68 to 96 
years, and their RHR was recorded using electrocardiography annually over a 4 years period (17). For 
each participant, linear regression analysis was used to estimate RHR mean value, trend in RHR (the 
slope of the regression line, in 2 bpm per year) and RHR variation (the standard deviation of the five 
residuals around the regression line, in 2 bpm). Long-term variation in RHR, but not RHR trend was 
independently associated with the risk of death: fully-adjusted HR=1.06 (95% CI: 1.02-1.12). The 
authors did not reveal independent association between any of the RHR variables and the risk of 
incident MI, however fully-adjusted HR for the RHR trend was 1.08 (95% CI: 0.95-1.23). Although 
the slope of the regression line based on the five RHR recordings is a better approximation of an 
individual long-term trend in RHR compared to the difference between two RHR measurements it 
does not provide a comprehensive picture of RHR changes over time. Effects of the RHR mean, RHR 
trend and RHR variation were adjusted for each other in the models, but  interaction between RHR 
trend and the other RHR variables was not taken into account. The inconsistency with our results can 
also be due to differences in the study populations, shorter study period, and lack of power in the USA 
study.  
Another paper from the above mentioned Cardiovascular Health Study used seven annual 
recordings of RHR, and ran Cox regression analysis with RHR as a time-varying covariate to estimate 
its effect on all-cause mortality (18). The authors concluded that elevations of RHR over the course of 
6 years were associated with an increased risk of mortality. Although it is an accurate way to assess 
the association between RHR and the outcome as the most resent RHR value is consistently used for 
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the prognostic estimation, this method does not provide any information on RHR change over time or 
its effect on mortality. 
RHR is a low-cost, clinical parameter that is easily and quickly measured and can be used as 
an important prognostic marker not only for secondary prevention in specific groups of patients, but 
for primary prevention in the general population as well. Elevated RHR causes chronic hemodynamic 
stress on the arterial wall, increases mean blood pressure, increases cardiac work and oxygen 
consumption, and desynchronizes ventricular muscle cells, thereby worsening coronary perfusion 
(25,). Elevated RHR is associated with a prothrombotic state (26). Through these possible underlying 
mechanisms, elevated RHR can independently increase the risk of hypertension and facilitate the 
progression of atherosclerosis, arrhythmias, acute cardiovascular events, and death. However, RHR 
can be changed, either intentionally or unintentionally (25). RHR in normal subjects is regulated by 
the pacemaker activity of the sinoatrial node cells, which are in turn influenced by many 
nonmodifiable factors, such as genetics, sex, and age, and modifiable factors like smoking, physical 
activity, blood pressure, and drugs (27).  
Long-term RHR trajectories provide additional diagnostic, prognostic, and therapeutic 
information for cardiovascular and overall health. Although the trajectories are correlated with the last 
measured RHR, the changes in RHR address additional information, such as control of sympathetic 
and parasympathetic activity. Single recordings do not depict longitudinal patterns in RHR and 
therefore may not be a proper measure of the total exposure (28). For example, increasing and 
decreasing RHR trajectories in our study crossed each other over the time period. Single recordings of 
RHR at the cross point would place these individuals together though they have different longitudinal 
patterns of RHR and are at different risk of CVD morbidity and mortality. However, this study was 
observational, and therefore we could not draw conclusions on causality. Further studies are needed to 
investigate an effect of induced RHR reduction on CVD risk. 
This is the first and only large population-based longitudinal study conducted on both sexes 
with a wide range of ages, with up to three measurements of RHR per participant over a 15-year 
period and 12 years of follow-up with respect to incident MI, incident AF, incident IS, CVD death 
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and total death. Another major strength of our study is our thorough methods of detection of MI, AF 
and IS cases. 
We applied statistical analysis that allowed us to identify detailed RHR trajectories during the 
15-year survey period. The most common way to construct categories of developmental trajectories 
for more than two repeated measurements so far is using assignment rules based on subjective 
categorization criteria. Although this method is reasonable, there are some important limitations, such 
as an a priori assumption of the existence of distinct developmental trajectories, and that the 
uncertainty about an individual’s group membership cannot be quantified in the form of probabilities 
(24). The trajectory analysis has the capacity to identify qualitatively distinct developmental 
progressions and to distinguish variations due to chance from real differences across individuals. As 
recommended, in order to choose the number of trajectories in the final models, we used both a 
careful weighting of formal statistical criteria against explanatory power and usability in the analyses 
(24). 
However, several limitations need to be mentioned. Many participants attended only two of 
the three surveys that could result in low robustness of latent class analysis and might have introduced 
some between groups bias. However, the supplementary figure demonstrates that the trajectory 
analysis managed well to assign participants to the trajectory groups. Moreover, a further adjustment 
of the risk analyses for the number of attended surveys per subject had virtually no effect on the 
results. In order to avoid potential bias the 2001 survey was defined as the final survey for trajectory 
modeling and the survey from which the follow-up period started. Thereby we lost some cases 
occurred between the 1994-95 and 2001 surveys among those who did not attend the 2001 survey. 
However, a sensitivity analysis with the follow-up started at the last survey attended showed almost 
identical results. Excluding participants who reported taking blood pressure medications notably 
reduced our sample size, which could have resulted in the loss of some cases, as hypertension is an 
important risk factor for MI, AF, and IS.  Unfortunately, we had no detailed information on treatment, 
such as type of drugs interacting with RHR or doses, to properly adjust for it. We did not include 
diastolic blood pressure in the analysis due to strong correlation with systolic blood pressure. Due to 
an inconsistency, we had to modify the variable of physical activity in the 1994-95 survey, and partly 
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in the 2001 survey, which led to figures that were quite different from those of other surveys. In 
addition, it is possible that there were persons with undiagnosed MI, AF, or IS. Finally, the 
associations were not adjusted for heart rate variability, cardiorespiratory fitness, markers of 
inflammation, and diet. 
 
Conclusion 
RHR is an established independent predictor of CVD and death, but it is modifiable and can change 
over time. Our findings showed that men with consistently low levels of RHR had the lowest risk of 
MI and total death, whereas men with constantly elevated RHR had the highest risk of these events. 
Substantially increased RHR over the survey period increased the risk of MI and total death, but it 
was still lower than that in individuals with constantly elevated RHR. Men with a substantial decrease 
in RHR over time had a lower risk of MI and total death compared to men with increasing or elevated 
RHR trajectories. The direction of the association and the point estimates of relative risk for MI in 
women were similar to men’s. The substantial decrease in RHR over time in women had protective 
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Figure 1. Flowchart of participants, the Tromsø Study1986-2001. 
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Completed questionnaire and attended at least one of the three Tromsø Study surveys 
from 1986-87 to 2001 
n=32,708; 55,529 visits: 
The 1986-87 survey: n=20,517 visits 
The 1994-95 survey: n=26,966 visits 
The 2001 s rvey: n=8046 visits 
Pregnancy and/or missing values  
n=595; 2560 visits: 
- from the 1986-87 survey, n=414 visits 
- from the 1994-95 survey, n=857 visits 
- from the 2001 survey, n=1289 visits 
 
 
Reported taking blood pressure medication  
n=2807; 5595 visits: 
- from the 1986-87 survey, n=1631 visits 
- from the 1994-95 survey, n=2624 visits 
- from the 2001 survey, n=1340 visits 
 
 
 Death or emigration from Norway before 28 August 2001  
n=1698; 2342 visits: 
- from the 1986-87 survey, n=1087 visits 
- from the 1994-95 survey, n=1255 visits 
- from the 2001 survey, n=0 visits 
 
Attending only one of the three surveys  
n=13,130 
- from the 1986-87 survey, n=4248 
- from the 1994-95 survey, n=8158 
- from the 2001 survey, n=724 
 
Data used in analysis 
n=14,208; 31,902 visits: 
The 1986-87 survey: n=13,137 visits 
The 1994-95 survey: n=14,072 visits 





Figure 2. Resting heart rate trajectories in men and women, the Tromsø Study, 1986-2001. 
 
Sex-specific means and 95% confidence intervals of resting heart rate (beats per minute, bpm) presented according the three Tromsø Study surveys and the 
five resting heart rate trajectory groups. Resting heart rate trajectory groups were determined using latent class models (SAS Proc Traj). 


































Low (n=1542) Moderate (n=3716)



































Low (n=1800) Moderate (n=4284)
Decreasing (n=630) Increasing (n=504)
Elevated (n=92)
Table 1. Descriptive characteristics of RHR trajectory groups in men, the Tromsø Study, 1986-2001.a 












N, 1986-87 1443 3526 723 641 180  
N, 1994-95 1532 3681 750 683 188  
N, 2001 481 1073 204 257 53  
Age, years       
   1986-87 38.2 (10.1) 37.6 (10.1) 37.9 (10.3) 38.9 (9.9) 39.4 (10.8) 0.004 
   1994-95 46.7 (11.0) 45.8 (10.6) 45.9 (10.6) 47.6 (10.7) 47.7 (11.1) <0.001 
   2001 60.8 (12.1) 59.2 (12.0) 58.7 (11.6) 59.7 (11.4) 62.0 (10.4) 0.051 
RHR, bpm       
   1986-87 58.1 (6.0) 71.6 (7.0) 90.9 (6.2) 77.8 (6.2) 102.3 (9.7) <0.001 
   1994-95 57.8 (5.9) 69.9 (6.7) 80.0 (7.5) 86.8 (7.8) 100.0 (9.2) <0.001 
   2001 56.8 (5.8) 68.4 (7.7) 73.5 (6.0) 87.3 (7.7) 95.9 (13.5) <0.001 
Systolic blood pressure, mmHg       
   1986-87 130.2 (11.5) 131.2 (11.6) 136.0 (12.7) 133.5 (12.8) 142.0 (16.3) <0.001 
   1994-95 131.9 (13.6) 133.5 (13.7) 138.2 (15.5) 139.0 (16.2) 146.0 (18.6) <0.001 
   2001 131.5 (17.3) 132.9 (17.7) 138.6 (18.0) 140.5 (21.4) 146.4 (20.2) <0.001 
Total cholesterol, mmol/L       
   1986-87 5.79 (1.18) 6.00 (1.23) 6.22 (1.23) 6.15 (1.12) 6.23 (1.12) <0.001 
   1994-95 5.83 (1.15) 6.05 (1.18) 6.23 (1.22) 6.26 (1.18) 6.24 (1.12) <0.001 
   2001 5.37 (1.01) 5.58 (1.10) 5.74 (1.16) 5.86 (1.05) 5.45 (1.13) <0.001 
HDL cholesterol, mmol/L       
   1986-87 1.43 (0.34) 1.39 (0.32) 1.36 (0.34) 1.35 (0.32) 1.36 (0.38) <0.001 
   1994-95 1.39 (0.35) 1.36 (0.35) 1.33 (0.35) 1.32 (0.38) 1.34 (0.35) <0.001 
   2001 1.35 (0.37) 1.29 (0.36) 1.27 (0.35) 1.26 (0.38) 1.28 (0.34) <0.001 
Triglycerides, mmol/L       
   1986-87 1.41 (0.76) 1.58 (0.92) 1.82 (1.14) 1.66 (0.98) 1.79 (1.05) <0.001 
   1994-95 1.56 (0.96) 1.75 (1.10) 1.93 (1.27) 2.09 (1.35) 1.97 (1.31) <0.001 
   2001 1.44 (0.81) 1.65 (1.01) 1.79 (1.09) 1.93 (1.20) 1.70 (1.43) <0.001 
BMI, kg/m2       
   1986-87 24.6 (2.4) 24.7 (2.9) 25.0 (3.3) 25.3 (3.1) 24.9 (3.5) <0.001 
   1994-95 25.2 (2.7) 25.4 (3.1) 25.7 (3.5) 26.2 (3.6) 25.7 (3.8) <0.001 
   2001 25.5 (3.0) 25.9 (3.4) 26.1 (3.5) 26.8 (3.9) 25.1 (3.8) <0.001 
Physical activity, %       
   1986-87: 
     - sedentary 
     - moderate 






















   1994-95: 
     - sedentary 
     - moderate 






















   2001: 
     - sedentary 
     - moderate 






















Smoking status, %       
   1986-87 374 (25.1) 1662 (45.8) 452 (61.3) 337 (50.5) 110 (60.0) <0.001 
   1994-95 328 (21.6) 1463 (40.1) 391 (52.5) 317 (46.7) 95 (51.3) <0.001 
   2001 80 (18.4) 345 (34.8) 84 (47.7) 101 (43.9) 26 (51.9) <0.001 
RHR: resting heart rate, bpm: beats per minute, HDL: high-density lipoprotein, BMI: body mass index. 
aValues are mean (standard deviation) or number (%); the means (except age) and percentages are adjusted for age between the surveys and trajectory groups 
using linear mixed models or generalized estimating equations, respectively. 
Table 2. Descriptive characteristics of RHR trajectory groups in women, the Tromsø Study, 1986-2001.a 












   N, 1986-87 1646 3867 598 432 81  
   N, 1994-95 1779 4245 624 498 92  
   N, 2001 654 1511 199 235 26  
Age at baseline, years       
   1986-87 37.1 (9.1) 36.6 (9.2) 36.2 (9.3) 37.7 (9.6) 38.4 (9.7) 0.013 
   1994-95 45.7 (10.2) 45.6 (10.6) 44.7 (10.0) 47.6 (11.4) 47.4 (11.1) <0.001 
   2001 58.8 (11.0) 58.9 (11.7) 57.1 (11.0) 60.1 (12.0) 59.7 (13.3) 0.125 
RHR, bpm       
   1986-87 64.8 (6.1) 78.3 (7.5) 99.2 (6.8) 84.3 (6.3) 111.1 (11.7) <0.001 
   1994-95 63.0 (6.0) 74.9 (7.0) 87.1 (8.1) 92.1 (8.3) 108.9 (10.9) <0.001 
   2001 61.6 (6.5) 73.3 (7.3) 80.0 (7.2) 92.5 (6.8) 111.6 (16.6) <0.001 
Systolic blood pressure, mmHg       
   1986-87 120.8 (10.8) 124.2 (11.7) 132.7 (14.6) 127.5 (14.7) 143.3 (18.1) <0.001 
   1994-95 122.5 (14.9) 126.2 (15.8) 133.0 (18.0) 133.3 (18.2) 150.7 (23.6) <0.001 
   2001 123.4 (21.8) 126.9 (21.7) 132.1 (20.1) 133.0 (22.9) 151.9 (23.3) <0.001 
Total cholesterol, mmol/L       
   1986-87 5.83 (1.15) 5.99 (1.20) 6.20 (1.23) 6.10 (1.20) 6.46 (1.37) <0.001 
   1994-95 5.75 (1.25) 5.93 (1.29) 6.22 (1.36) 6.06 (1.31) 6.28 (1.29) <0.001 
   2001 5.31 (1.14) 5.49 (1.21) 5.63 (1.15) 5.55 (1.20) 5.55 (1.26) <0.001 
HDL cholesterol, mmol/L       
   1986-87 1.72 (0.37) 1.68 (0.37) 1.67 (0.36) 1.67 (0.38) 1.70 (0.34) <0.001 
   1994-95 1.69 (0.40) 1.63 (0.39) 1.65 (0.42) 1.61 (0.43) 1.68 (0.38) <0.001 
   2001 1.54 (0.40) 1.50 (0.40) 1.51 (0.42) 1.44 (0.42) 1.54 (0.38) <0.001 
Triglycerides, mmol/L       
   1986-87 1.05 (0.48) 1.17 (0.60) 1.27 (0.66) 1.21 (0.55) 1.25 (0.55) <0.001 
   1994-95 1.12 (0.65) 1.27 (0.79) 1.35 (0.81) 1.43 (0.88) 1.31 (0.71) <0.001 
   2001 1.14 (0.65) 1.27 (0.75) 1.30 (0.66) 1.44 (0.80) 1.41 (1.09) <0.001 
BMI, kg/m2       
   1986-87 23.4 (2.9) 23.4 (3.2) 23.4 (3.8) 23.9 (3.8) 23.4 (4.2) 0.032 
   1994-95 24.2 (3.5) 24.4 (3.8) 24.3 (4.4) 25.0 (5.0) 24.5 (4.5) <0.001 
   2001 24.7 (4.0) 25.0 (4.2) 25.2 (4.7) 25.6 (5.3) 25.4 (4.9) 0.005 
Physical activity, %       
   1986-87: 
     - sedentary 
     - moderate 






















   1994-95: 
     - sedentary 
     - moderate 






















   2001: 
     - sedentary 
     - moderate 






















Smoking status, %       
   1986-87 564 (30.5) 1903 (44.4) 337 (50.9) 225 (48.1) 42 (44.4) <0.001 
   1994-95 527 (30.3) 1793 (43.0) 313 (50.6) 243 (50.8) 37 (41.8) <0.001 
   2001 157 (30.9) 468 (40.9) 72 (45.8) 93 (50.9) 6 (42.5) <0.001 
RHR: resting heart rate, bpm: beats per minute, HDL: high-density lipoprotein, BMI: body mass index. 
aValues are mean (standard deviation) or number (%); the means (except age) and percentages are adjusted for age between the surveys and trajectory groups 
using linear mixed models or generalized estimating equations, respectively. 
Table 3. Associations of RHR trajectory group with myocardial infarction, atrial fibrillation, ischemic stroke, cardiovascular death, and total death, the 
Tromsø Study, 1986-2001. 
 Men    Women   
 Cases (%) HR (95% CI)a HR (95% CI)b  Cases (%) HR (95% CI)a HR (95% CI)b 
Myocardial infarction   406/6351   185/6903 
    Low 68 (4.8) 1.00 1.00  28 (1.7) 1.00 1.00 
    Moderate 206 (6.0) 1.37 (1.04-1.81) 1.15 (0.87-1.52)  114 (2.8) 1.68 (1.11-2.55) 1.27 (0.84-1.93) 
    Decreasing 52 (7.5) 1.74 (1.21-2.50) 1.12 (0.77-1.63)  14 (2.3) 1.57 (0.83-2.98) 0.95 (0.49-1.83) 
    Increasing 58 (9.2) 2.00 (1.41-2.84) 1.36 (0.95-1.95)  24 (5.0) 2.52 (1.46-4.36) 1.50 (0.86-2.61) 
    Elevated 22 (12.5) 2.90 (1.80-4.70) 1.83 (1.11-3.02)  5 (5.7) 3.33 (1.29-8.62) 1.79 (0.67-4.77) 
Atrial fibrillation  439/6462   225/6904 
    Low 118 (8.2) 1.00 1.00  54 (3.2) 1.00 1.00 
    Moderate 222 (6.3) 0.89 (0.71-1.11) 0.86 (0.69-1.08)  135 (3.3) 0.99 (0.72-1.36) 0.89 (0.65-1.22) 
    Decreasing 45 (6.4) 0.92 (0.66-1.30) 0.87 (0.61-1.23)  7 (1.2) 0.40 (0.18-0.87) 0.31 (0.14-0.68) 
    Increasing 46 (7.3) 0.94 (0.67-1.33) 0.87 (0.61-1.23)  25 (5.3) 1.30 (0.81-2.10) 1.04 (0.64-1.68) 
    Elevated 8 (4.7) 0.67 (0.33-1.36) 0.61 (0.30-1.27)  4 (4.6) 1.55 (0.56-4.29) 0.84 (0.29-2.41) 
Ischemic stroke  231/6513   137/6936 
    Low 54 (3.7) 1.00 1.00  26 (1.5) 1.00 1.00 
    Moderate 112 (3.2) 0.99 (0.72-1.37) 0.82 (0.59-1.15)  80 (2.0) 1.27 (0.82-1.98) 1.09 (0.70-1.71) 
    Decreasing 34 (4.8) 1.54 (1.00-2.37) 1.03 (0.66-1.61)  8 (1.3) 0.96 (0.43-2.12) 0.68 (0.30-1.53) 
    Increasing 23 (3.6) 1.03 (0.63-1.68) 0.70 (0.42-1.15)  20 (4.1) 2.24 (1.25-4.03) 1.69 (0.93-3.06) 
    Elevated 8 (4.5) 1.44 (0.69-3.03) 0.82 (0.38-1.76)  3 (3.4) 2.15 (0.65-7.10) 1.13 (0.33-3.92) 
CVD death  179/6898   98/7310 
    Low 28 (1.8) 1.00 1.00  14 (0.8) 1.00 1.00 
    Moderate 84 (2.3) 1.43 (0.93-2.20) 1.20 (0.78-1.85)  63 (1.5) 1.76 (0.98-3.14) 1.46 (0.81-2.62) 
    Decreasing 21 (2.8) 1.81 (1.03-3.19) 1.17 (0.65-2.09)  9 (1.4) 2.35 (1.01-5.43) 1.55 (0.66-3.64) 
    Increasing 34 (4.9) 2.67 (1.62-4.41) 1.86 (1.11-3.11)  10 (2.0) 1.67 (0.74-3.77) 1.16 (0.51-2.65) 
    Elevated 12 (6.4) 3.67 (1.87-7.23) 1.94 (0.95-3.96)  2 (2.2) 2.07 (0.47-9.10) 0.96 (0.21-4.40) 
Total death  707/6898   472/7310 
    Low 118 (7.7) 1.00 1.00  98 (5.4) 1.00 1.00 
    Moderate 349 (9.4) 1.47 (1.19-1.81) 1.26 (1.02-1.56)  273 (6.4) 1.14 (0.91-1.44) 1.01 (0.80-1.27) 
    Decreasing 86 (11.4) 1.81 (1.37-2.39) 1.37 (1.03-1.82)  34 (5.4) 1.14 (0.77-1.68) 0.87 (0.58-1.29) 
    Increasing 112 (16.1) 2.33 (1.80-3.02) 1.82 (1.40-2.38)  58 (11.5) 1.66 (1.20-2.30) 1.31 (0.94-1.82) 
    Elevated 42 (22.2) 3.54 (2.49-5.03) 2.44 (1.69-3.53)  9 (9.8) 1.72 (0.87-3.41) 1.17 (0.58-2.35) 
RHR: resting heart rate, HR: hazard ratio, CI: confidence interval, CVD: cardiovascular disease. 
aAdjusted for age. bAdjusted for age, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, triglycerides, body mass index and 
physical activity, and smoking at last attended survey. 
